SCHEMBL12522089

SCHEMBL12522089

CC[C@@]1(C)CC=C2C(CCC3[C@](C)(COC(=O)CN4CCN(S(=O)(=O)c5ccc(OC)cc5)CC4)CCC[C@@]23C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.43
▸ PKM P14618 3/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ NSD2 O96028 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ PTGS1 P23219 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CHRNB2 P17787 2/20 0.40
▸ CHRNB4 P30926 2/20 0.40
▸ CHRNA3 P32297 2/20 0.40
▸ CHRNA4 P43681 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12522458 0.93 KMT2A (0.40) ALDH1A1CYP2C19KMT2APTGS1CYP1A2
SCHEMBL267588 0.90 PTGS1 (0.50) ALDH1A1PKMCYP3A4CYP2D6CYP2C19
SCHEMBL280402 0.90 ALDH1A1 (0.43) ALDH1A1PKMCYP3A4CYP2D6CYP2C19
SCHEMBL12522092 0.88 PTGS1 (0.43) PTGS1
SCHEMBL267408 0.84 PTGS1 (0.51) ALDH1A1KMT2APTGS1
SCHEMBL1195191 0.77 PTGS1 (0.56) PTGS1
SCHEMBL6007560 0.74 PTGS1 (0.49) PTGS1
SCHEMBL262480 0.72 PTGS1 (0.58) PTGS1
SCHEMBL267398 0.72 PTGS1 (0.58) PTGS1
SCHEMBL28522897 0.71 ALDH1A1 (0.68) ALDH1A1PKMCYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238634-A1 INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS NEREUS PHARMACEUTICALS, INC. (US) 2012-09-20 — — US disclosed
EP-2311795-A2 Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators Nereus Pharmaceuticals, Inc. (US) 2011-04-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238634-A1 INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS IL1A, IL1B, TNF ALDH1A1 2662/4885PKM 2835/4885CYP3A4 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback